Loading...
•
Dec 31, 2024
Legend Biotech Q4 2024 Earnings Report
Legend Biotech reported strong Q4 2024 revenue growth, driven by CARVYKTI sales.
Key Takeaways
Legend Biotech reported Q4 2024 revenue of $186.5 million, significantly increasing from $79.5 million in Q4 2023. The company posted a net income of $26.3 million, reversing a prior-year net loss of $144.8 million. EPS was $0.07, while adjusted EPS was -$0.16. The results reflect strong CARVYKTI sales and licensing revenue growth.
Total revenue grew 134.7% year-over-year to $186.5 million.
Net income of $26.3 million, reversing a loss of $144.8 million in Q4 2023.
EPS of $0.07, while adjusted EPS was -$0.16.
CARVYKTI sales continued driving revenue growth, reaching $334 million.
Legend Biotech
Legend Biotech
Legend Biotech Revenue by Segment
Revenue by Segment
License Revenue
CapyFin.comCollaboration Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
Legend Biotech expects continued growth driven by CARVYKTI commercialization and new licensing opportunities.
Positive Outlook
- CARVYKTI is expected to expand its market leadership.
- New licensing deals with Novartis create additional revenue streams.
- Manufacturing expansion with Novartis will enhance production capabilities.
- Increased regulatory approvals are broadening treatment accessibility.
- Strong cash reserves support further investments and R&D.
Challenges Ahead
- R&D expenses remain high, impacting profitability.
- Ongoing expansion requires significant capital investment.
- Regulatory risks could impact approval timelines.
- Macroeconomic factors may affect drug pricing and reimbursement.
- Foreign exchange fluctuations continue to influence financial results.